Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.kint.2023.05.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tolvaptan versus fluid restriction in moderate-profound hyponatremia: An open-label randomized clinical trial.
J Clin Endocrinol Metab
July 2025
Austin Health Department of Endocrinology, Heidelberg, VIC, Australia.
Context: Current first-line therapy for hyponatremia, fluid restriction (FR), is often unsuccessful. Tolvaptan, an arginine vasopressin V2-receptor antagonist, is effective however concerns about plasma sodium (pNa) overcorrection risk have limited uptake.
Objective: To compare the efficacy of tolvaptan and fluid restriction, with a pre-specified protocol for dextrose 5% intervention if sodium correction targets were exceeded.
Background: Electrolyte disorders are among the most frequent presentations in emergency internal medicine and may represent initial manifestations of underlying endocrine disease. This review highlights the pathophysiological background, diagnostic strategies and therapeutic recommendations for electrolyte imbalances in endocrine emergencies.
Content: Hyponatremia still marks the most prevalent electrolyte disorder and may indicate underlying adrenal insufficiency, hypopituitarism, the syndrome of inappropriate antidiuresis (SIAD), or immunotherapy-induced endocrinopathies.
Systematic review of pharmacological, complementary, and alternative therapies for the prevention of calcium oxalate stones.
Asian J Urol
April 2025
Department of Urology, University of California San Diego Health, San Diego, CA, USA.
Objective: Several therapeutic modalities for the prevention of calcium oxalate (CaOx) stones have been studied, but only a select few of these modalities have been incorporated into the American Urological Association guidelines. Our study aimed to organize and interrogate existing research that may be promising for CaOx prevention.
Methods: A literature search was conducted using MEDLINE and Embase from inception to November 16, 2022.
The role of vasopressin deficiency in the fluid intake suppression hyper-responsivity to central glucagon-like peptide-1 in the Brattleboro rat.
Physiol Behav
September 2025
Department of Psychology, the State University of New York at Buffalo, Buffalo, NY USA; Department of Biological Sciences, the State University of New York at Buffalo, Buffalo, NY USA; Center for Ingestive Behavior Research, the State University of New York at Buffalo, Buffalo, NY USA. Electronic ad
Food and fluid intakes are physiologically and behaviorally intertwined; one often affects the other. Likewise, pharmacological manipulations that influence eating often affect drinking. For example, glucagon-like peptide-1 (GLP-1) suppresses both eating and fluid intake, but the respective elements of the GLP-1 system remain unparsed.
View Article and Find Full Text PDFPharmacotherapy in kidney disease: what it takes to move from general guidance to specific recommendations to stratified subgroups of patients - the tale of autosomal dominant polycystic kidney disease (ADPKD).
Expert Opin Drug Metab Toxicol
June 2025
Division of Pharmacy and Optometry, The University of Manchester Centre for Applied Pharmacokinetic Research, Manchester, UK.
Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary condition that leads to a range of systemic manifestations. Many of them require pharmacological interventions. Most patients receive multidrug therapy.
View Article and Find Full Text PDF